Nymyo Kit
Product Images NDC 51862-645

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Nymyo (NDC 51862-645). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mayne Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 01)

A table titled 'Instructions for Administration of Nymyo' providing detailed guidance on how to start Nymyo oral contraceptive pills, including Day 1 and Sunday start methods, tablet colors for active and inactive pills, and instructions for switching from other contraceptive methods such as transdermal patch, vaginal ring, injection, intrauterine contraceptive, and implant. It emphasizes the use of additional non-hormonal contraception when appropriate and refers to the FDA-approved patient labeling for complete instructions.*

FDA Label Image

2 (Image 02)

A table titled 'Instructions for Missed Nymyo Tablets' providing guidance on what to do if one or two active tablets are missed during various weeks of the dosing schedule. It includes instructions about continuing the pack, starting a new pack, and advises the use of additional non-hormonal contraception such as condoms and spermicide as backup if sex occurs within 7 days after missed tablets.*

FDA Label Image

3 (Image 03)

Chemical structure diagrams of the active ingredients Norgestimate and Ethinyl Estradiol, shown side by side with labeled molecular groups, associated with the prescription drug Nymyo.*

FDA Label Image

4 (Image 04)

A data table titled 'Summary of NGMN, NG and EE pharmacokinetic parameters,' presenting the mean and standard deviation of pharmacokinetic parameters for Norgestimate (NGMN and NG) and Ethinyl Estradiol (EE) 0.25 mg/0.035 mg tablets during a three-cycle study. It includes measured values for Cmax, tmax, AUC0-24h, and t1/2 across different cycles and days, with explanatory footnotes for terms and units.*

FDA Label Image

5 (Image 05)

FDA Label Image

6 (Image 06)

An illustration depicting contraceptive effectiveness categorized by pregnancy rates per 100 women in one year. It lists various birth control methods from most to least effective, including implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal rings with hormones, condoms, diaphragm, behavioral methods like abstaining during fertile days, spermicide, withdrawal, and no birth control.*

FDA Label Image

7 (Image 07)

Nymyo kit contains a 28-tablet blister card with norgestimate and ethinyl estradiol. The blister card includes blue (active) pills and white (inactive) pills arranged in a weekly layout from Sunday to Saturday. The label shows directions to take the pills from left to right each week. The product is labeled by Mayne Pharma Inc.*

FDA Label Image

8 (Image 08)

An instructional diagram showing how to use the Nymyo kit pill pack. The illustration highlights the starting point for Sunday and Day 1 starters, advises placing a day label sticker corresponding to the first day of the period, and shows the direction to take pills from left to right each week. The pill pack contains rows of blue (active) and white (inactive) pills, labeled by day of the week.*

FDA Label Image

9 (Image 09)

FDA Label Image

10 (Image 10)

Nymyo 0.25 mg/0.035 mg kit packaging label for tablets containing norgestimate and ethinyl estradiol. Distributed by Mayne Pharma Inc., Greenville, NC. The label notes a 28-day regimen with 6 blister cards of 28 tablets each, and features barcode and product identification details. The package instructs storage at 20° to 25°C and cautions to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.